Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1994 1
2000 1
2003 2
2006 1
2007 2
2008 1
2009 1
2010 2
2011 7
2012 6
2013 4
2014 9
2015 7
2016 3
2017 2
2018 4
2019 2
2020 5
2021 3
2022 3
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.
Neppelenbroek SIM, Geurts YM, Aleman BMP, Lugtenburg PJ, Rademakers SE, de Weijer RJ, Schippers MGA, Ta BDP, Plattel WJ, Zijlstra JM, van der Maazen RWM, Nijziel MR, Ong F, Schimmel EC, Posthuma EFM, Kersten MJ, Böhmer LH, Muller K, Koene HR, Te Boome LCJ, Bilgin YM, de Jongh E, Janus CPM, van Leeuwen FE, Schaapveld M. Neppelenbroek SIM, et al. Among authors: nijziel mr. J Clin Oncol. 2024 Feb 15:JCO2301386. doi: 10.1200/JCO.23.01386. Online ahead of print. J Clin Oncol. 2024. PMID: 38359378
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma.
Geurts YM, Neppelenbroek SIM, Aleman BMP, Janus CPM, Krol ADG, van Spronsen DJ, Plattel WJ, Roesink JM, Verschueren KMS, Zijlstra JM, Koene HR, Nijziel MR, Schimmel EC, de Jongh E, Ong F, Te Boome LCJ, van Rijn RS, Böhmer LH, Ta BDP, Visser HPJ, Posthuma EFM, Bilgin YM, Muller K, van Kampen D, So-Osman C, Vermaat JSP, de Weijer RJ, Kersten MJ, van Leeuwen FE, Schaapveld M. Geurts YM, et al. Among authors: nijziel mr. ESMO Open. 2024 Feb;9(2):102248. doi: 10.1016/j.esmoop.2024.102248. Epub 2024 Feb 12. ESMO Open. 2024. PMID: 38350338 Free PMC article.
Risk of male breast cancer after Hodgkin lymphoma.
de Vries S, Krul IM, Schaapveld M, Janus CPM, Rademakers SE, Roesink JM, Nijziel MR, Bilgin YM, Aleman BMP, van Leeuwen FE. de Vries S, et al. Among authors: nijziel mr. Blood. 2023 Aug 31;142(9):806-811. doi: 10.1182/blood.2023020940. Blood. 2023. PMID: 37390297
The upper extremity postthrombotic syndrome score: an international Delphi consensus study to determine the score's functional disability component.
Schropp L, Cats RB, de Kleijn RJCMF, van Hattum ES, Middeldorp S, Nijkeuter M, Westerink J, Petri BJ, de Borst GJ; Upper Extremity PTS group. Schropp L, et al. Res Pract Thromb Haemost. 2023 Jan 19;7(1):100051. doi: 10.1016/j.rpth.2023.100051. eCollection 2023 Jan. Res Pract Thromb Haemost. 2023. PMID: 36873563 Free PMC article.
Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma.
Krul IM, Boekel NB, Kramer I, Janus CPM, Krol ADG, Nijziel MR, Zijlstra JM, van der Maazen RWM, Roesink JM, Jacobse JN, Schaapveld M, Schmidt MK, Opstal-van Winden AWJ, Sonke GS, Russell NS, Aleman BMP, van Leeuwen FE. Krul IM, et al. Among authors: nijziel mr. Cancer. 2022 Dec 15;128(24):4285-4295. doi: 10.1002/cncr.34464. Epub 2022 Oct 25. Cancer. 2022. PMID: 36281718 Free article.
Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function.
Tullemans BME, Karel MFA, Léopold V, Ten Brink MS, Baaten CCFMJ, Maas SL, de Vos AF, Eble JA, Nijziel MR, van der Vorst EPC, Cosemans JMEM, Heemskerk JWM, Claushuis TAM, Kuijpers MJE. Tullemans BME, et al. Among authors: nijziel mr. EJHaem. 2021 Aug 10;2(4):685-699. doi: 10.1002/jha2.269. eCollection 2021 Nov. EJHaem. 2021. PMID: 35845214 Free PMC article.
Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.
Raa DGT, van der Straten L, van Gelder M, Kersting S, Levin MD, Mous R, van der Straaten HM, Nijziel MR, van der Spek E, Posthuma EFM, Visser HPJ, van der Klift M, de Heer K, Bellido M, Doorduijn JK, Bruns AHW, Raijmakers RAP, Kater AP; HOVON CLL study group. Raa DGT, et al. Among authors: nijziel mr. Leuk Lymphoma. 2022 Oct;63(10):2276-2289. doi: 10.1080/10428194.2022.2084731. Epub 2022 Jun 23. Leuk Lymphoma. 2022. PMID: 35737364
68 results